Clinical trials: Overweight or Obese
Obesity, Overweight
A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity
The purpose of this clinical study is to find out if NNC0113-5840 is safe for treating people with excess body weight. There are 2 study treatments in this study, participants will get either NNC0113-5840 (the product being…
- Trial name
- NCT07566390
- Testing
- NNC0113-5840
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Novo Nordisk A/S
Chronic Weight Management
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight
This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ASC35 injection
- Trial name
- NCT07842640
- Testing
- ASC35 Injection B, for subcutaneous use, Tirzepatide
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Ascletis Pharma (China) Co., Limited
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).
- Trial name
- ATTAIN-CN (NCT07790861)
- Testing
- Orforglipron
- Where
- 13 sites in China
- Volunteers
- 192 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3841136 compared with placebo in adult participants with obesity or…
- Trial name
- NCT06230523
- Testing
- Eloralintide
- Where
- 43 sites in United States
- Volunteers
- 263 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide.
- Conditions
- Overweight, Obesity, Type 2 Diabetes
- Trial name
- RENEW 2 (NCT07220759)
- Testing
- Cagrilintide
- Where
- 67 sites in United States, Argentina and 9 more
- Volunteers
- 330 people
- Sponsor
- Novo Nordisk A/S
Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants who are overweight or obese…
- Trial name
- NCT06628362
- Testing
- Enicepatide
- Where
- 70 sites in United States, Argentina and 4 more
- Volunteers
- 447 people
- Sponsor
- Carmot Therapeutics, Inc.
Healthy Participants
A Study of Safety of SUN-0864 and How it is Processed by and Affects the Body in Healthy Adults and Healthy Adults Who Are Overweight or Obese.
This Phase 1, first-in-human study will evaluate the safety and tolerability of SUN-0864, how the body processes SUN-0864, and how SUN-0864 affects the body in healthy adults and otherwise healthy adults who are overweight or…
- Trial name
- NCT07905560
- Testing
- SUN-0864 (Formulation 1) or SUN-0864 (Formulation 2)
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Superluminal Medicines, Inc.
Safety, Healthy Subjects
A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent
This is a phase I, randomized, blinded study to evaluate the safety and pharmacokinetics of MEDI0382 following single dose administration to overweight/obese subjects of Japanese or Chinese descent
- Trial name
- NCT03385369
- Testing
- MEDI0382
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Healthy Volunteer
A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.
The purpose of this study is to assess the adverse events, tolerability, and Pharmacokinetics (PK) of subcutaneous injections of ABBV-295 in healthy adult Japanese participants with overweight or obesity.
- Trial name
- NCT07514260
- Testing
- ABBV-295
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- AbbVie
Obesity
Study to Compare and Evaluate the Safety and Pharmacokinetics After Subcutaneous Injection of HUC2-676 or HUC2-676-R in Healthy Adult Subjects
The trial uses a randomized, open-label, single-dose administration per period, and a 2 x 2 crossover design where subjects receive both treatments sequentially with a washout.
- Trial name
- NCT07337174
- Testing
- HUC2-676, HUC2-676-R
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
Adults With Overweight/Obesity and Type 2 Diabetes
A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
The goal of this clinical trial is to learn if AT673 contributes to additional weight loss and glycemic control when given with semaglutide in participants with overweight/obesity and type 2 diabetes.
- Trial name
- NCT07724340
- Testing
- AT673 low dose, AT673 high dose
- Where
- 8 sites in United States
- Volunteers
- 150 people
- Sponsor
- Antag Therapeutics
Obesity
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
This study is open to adults who are at least 18 years old and have a body mass index (BMI) of 30 kg/m² or more, or a BMI of 27 kg/m² or more and at least one health problem related to their weight.
- Trial name
- SYNCHRONIZE™-1 (NCT06066515)
- Testing
- survodutide
- Where
- 118 sites in United States, Australia and 12 more
- Volunteers
- 726 people
- Sponsor
- Boehringer Ingelheim
Obesity
Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity
This study evaluated the safety of VTX3232 administered alone or in combination with semaglutide in participants with obesity. Approximately 160 participants were randomized to receive VTX3232 30 mg, placebo, VTX3232 30 mg in…
- Trial name
- NCT06771115
- Testing
- VTX3232 30 mg, VTX3232 30 mg in combination with semaglutide
- Where
- 14 sites in United States
- Volunteers
- 175 people
- Sponsor
- Zomagen Biosciences Ltd.
Urinary Incontinence,Stress
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron works in adult female participants with stress urinary incontinence (SUI) who have…
- Trial name
- RESTRAIN-SUI (NCT07202884)
- Testing
- Orforglipron
- Where
- 136 sites in United States, Canada and 8 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company
Otherwise Healthy Overweight or Obese
A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of PHP-303 in Otherwise Healthy Overweight or Obese Subjects
This is a Phase 1, randomized, double-blind, placebo-controlled multiple-ascending dose (MAD) study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of PHP-303 in otherwise healthy overweight or obese…
- Trial name
- NCT03775278
- Testing
- PHP-303
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- pH Pharma
Obesity
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 different doses of NNC0519-0130. Participants will take 1-2 injections once a week.
- Trial name
- NCT06326060
- Testing
- NNC0519-0130, Tirzepatide
- Where
- 70 sites in United States, Australia and 1 more
- Volunteers
- 354 people
- Sponsor
- Novo Nordisk A/S
Weight Loss
Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27kg/m2) adults with at least one weight-related comorbidity without type…
- Trial name
- NCT07868835
- Testing
- VK2735
- Volunteers
- 560 people
- Sponsor
- Viking Therapeutics, Inc.
Obesity, Overweight
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits.
- Trial name
- NCT04881760
- Testing
- LY3437943
- Where
- 28 sites in United States, Puerto Rico
- Volunteers
- 338 people
- Sponsor
- Eli Lilly and Company
Healthy, Obesity
A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity
The main objective of this trial is to establish the bioequivalence of survodutide in a pre-filled syringe (reference product [formulation A]) and in a vial (test product [formulation B2]) in male and female trial participants…
- Trial name
- NCT07768813
- Testing
- Survodutide formulation A, Survodutide formulation B2
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Obesity, Overweight
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes.
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- ATTAIN-2 (NCT05872620)
- Testing
- Orforglipron
- Where
- 136 sites in United States, Argentina and 9 more
- Volunteers
- 1,613 people
- Sponsor
- Eli Lilly and Company